Achieving Immune Activation by Suppressing the IDO1 Checkpoint with Sono-Targeted Biobromination for Antitumor Combination Immunotherapy
Journal of the American Chemical Society · 2024
DOI: 10.1021/jacs.4c07993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2024. Verfasst von Xiaoming Wen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Inorganic Coating Materials CAS, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, P. R. China. Hauptthemen laut MEDLINE: Indoleamine-Pyrrole 2,3,-Dioxygenase, Immunotherapy, Metal-Organic Frameworks. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Indoleamine-2,3-dioxygenase-1 (IDO1) pathogenically suppresses immune cell infiltration and promotes tumor cell immune escape by overmetabolizing tryptophan to N-formyl kynurenine in the tumor microenvironment (TME). However, it remains challenging for IDO1 immune checkpoint inhibitors to achieve a significant potency of progression-free survival. Here, we developed a breakthrough in IDO1 inhibition by sono-targeted biobromination reaction using immunostimulating hypobromic-P-phenylperoxydibenzoic acid-linked metallic organic framework nanomedicine (H-MOF NM) to remodel the TME from debrominated hypoxia into hypobromated normoxia and activate the IDO1 immune pathway with in vitro and in vivo remarkable antitumor efficacy. H-MOF NM contains Br+ and O- active ingredients with an enlarged band gap to deactivate IDO1 through an innovative biochemical mechanism, taking control over brominating IDO1 amino acid residues at the active sites in the remodeled TME and subsequently activating the immune response, including DC maturation, T-cell activation, and macrophage polarization. Importantly, the H-MOF NM achieves multiple immune responses with high tumor regression potency by combination sono-immunotherapy. This study describes an excellent IDO1 inhibition strategy through the development of immune biobrominative H-MOF nanomedicine and highlights efficient combination immunotherapy for tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Inorganic Coating Materials CAS, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, P. R. China.
- Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Science, Beijing 100049, P. R. China.
- Shanghai Key Laboratory of Orthopaedic Implant, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Engineering Research Center of Innovative O…
- Department of Oral Maxillofacial & Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for S…
- Department of Immunology, College of Basic Medicine & National Key Laboratory of Inflammation and Immunology, Naval Medical University, 800 Xiangyin Road, Shanghai 200433, P. R. China.
ORCID-Profile: Yongqiang Hao, Yingchun Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wen, X., Fu, J., Zhang, X., Meng, X., Tian, Y., Li, J., Yu, G., Hao, Y., & Zhu, Y. (2024). Achieving Immune Activation by Suppressing the IDO1 Checkpoint with Sono-Targeted Biobromination for Antitumor Combination Immunotherapy. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.4c07993
Vancouver
Wen X, Fu J, Zhang X, Meng X, Tian Y, Li J, et al. Achieving Immune Activation by Suppressing the IDO1 Checkpoint with Sono-Targeted Biobromination for Antitumor Combination Immunotherapy. Journal of the American Chemical Society. 2024. doi:10.1021/jacs.4c07993
BibTeX
@article{Wen2024,
author = {Wen, Xiaoming and Fu, Jingke and Zhang, Xiangkai and Meng, Xiaoyan and Tian, Yue and Li, Jing and Yu, Ganjun and Hao, Yongqiang and Zhu, Yingchun},
title = {Achieving Immune Activation by Suppressing the IDO1 Checkpoint with Sono-Targeted Biobromination for Antitumor Combination Immunotherapy},
journal = {Journal of the American Chemical Society},
year = {2024},
doi = {10.1021/jacs.4c07993}
}
EUVIMED